Cargando…
Overuse of short-acting β(2)-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme
BACKGROUND: Overuse of short-acting β(2)-agonists (SABA) may indicate poor asthma control and adverse health outcomes. Contemporary population-based data on use, risk factors and impact of SABA (over)use on asthma exacerbations and mortality are scarce, prompting initiation of the global SABINA (SAB...
Autores principales: | Nwaru, Bright I., Ekström, Magnus, Hasvold, Pål, Wiklund, Fredrik, Telg, Gunilla, Janson, Christer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160635/ https://www.ncbi.nlm.nih.gov/pubmed/31949111 http://dx.doi.org/10.1183/13993003.01872-2019 |
Ejemplares similares
-
Short‐acting β(2)‐agonist use and asthma exacerbations in Swedish children: A SABINA Junior study
por: Melén, Erik, et al.
Publicado: (2022) -
Oral corticosteroid use, morbidity and mortality in asthma: A nationwide prospective cohort study in Sweden
por: Ekström, Magnus, et al.
Publicado: (2019) -
Management and Risk of Mortality in Patients Hospitalised Due to a First Severe COPD Exacerbation
por: Janson, Christer, et al.
Publicado: (2020) -
High use of short-acting β(2)-agonists in COPD is associated with an increased risk of exacerbations and mortality
por: Janson, Christer, et al.
Publicado: (2023) -
Annual and Post-Exacerbation Follow-Up of Asthma Patients in Clinical Practice – A Large Population-Based Study in Sweden
por: Sandelowsky, Hanna, et al.
Publicado: (2022)